The Global biologics market was valued at $317.2 billion in 2022 and is expected to reach $669.0 billion by 2030, growing at a CAGR of 9.5% from 2022 to 2030. The market growth can be attributed to factors such as increasing prevalence of chronic diseases, advancements in biotechnology, and growing demand for personalized medicine.

Browse 215 market data Tables and 96 Figures spread through 312 Pages and in-depth TOC on "Biologics Market Size, Share & Trends Estimation Report By Outlook, By Region, And Segment Forecasts, 2022 - 2030" View detailed Table of Content here-https://www.contrivedatuminsights.com/product-report/biologics-market-248678/

Market Dynamics

Increasing prevalence of chronic diseases: The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders is driving demand for biologics. These conditions require long-term treatment, and biologics are often the preferred treatment option due to their effectiveness and fewer side effects.

Advancements in biotechnology: Advances in biotechnology have led to the development of new and innovative biologics with improved efficacy and safety profiles. Biotechnology has also enabled the production of biologics in larger quantities, making them more widely available.

High development costs: Developing and bringing biologics to market is a complex and expensive process. The cost of research and development is high, and the regulatory approval process can also be lengthy and expensive.

Stringent regulatory requirements: Biologics are subject to stringent regulatory requirements, which can be a barrier to entry for smaller companies. These requirements are necessary to ensure the safety and efficacy of biologics, but they can also slow down the development and approval process.

Scaling up production: While the demand for biodegradable plastics is growing, there are still challenges in scaling up production to meet that demand. This is particularly true for more complex or specialized types of biodegradable plastics.

Balancing performance and biodegradability: Biodegradable plastics must strike a balance between their performance characteristics and their ability to break down in the environment. Achieving this balance can be a challenge, particularly in applications where performance is critical.

Development of new biologics: There is a growing demand for new biologics that can address unmet medical needs, particularly in the areas of oncology, immunology, and rare diseases. Advances in biotechnology and genomics are creating new opportunities for the development of innovative biologics.

Expansion into emerging markets: Emerging markets such as Asia, Latin America, and the Middle East offer significant growth opportunities for the biologics market. These regions have large and growing populations, increasing healthcare spending, and a growing demand for biologics.

Cell and gene therapies are a rapidly growing segment of the biologics market. These therapies involve manipulating living cells or genes to treat or cure diseases. Examples of cell and gene therapies include CAR-T therapy for cancer and gene therapy for inherited genetic disorders. Biosimilars are similar to existing biologics and are approved for the same indications. They are generally less expensive than the original biologics and offer an opportunity for cost savings. Examples of biosimilars include Inflectra and Renflexis, which are biosimilars of Remicade.

Regional Analysis

The Asia Pacific region is a rapidly growing market for biologics, with countries such as China, Japan, and India being major players in the market. The region has a large and growing population, increasing healthcare spending, and a growing demand for biologics.

Latin America is a growing market for biologics, with countries such as Brazil, Mexico, and Argentina being major players in the market. The region has a large and growing population, increasing healthcare spending, and a growing demand for biologics.

The Middle East and Africa are emerging markets for biologics, with countries such as Saudi Arabia, the United Arab Emirates, and South Africa being major players in the market. The region has a growing demand for biologics, driven by increasing healthcare spending and a growing prevalence of chronic diseases.

Competitive Analysis

Some of the major players in the biologics market include Amgen, Roche, Johnson & Johnson, Novartis, AbbVie, Bristol-Myers Squibb, and Pfizer. These companies are investing heavily in research and development to introduce new and innovative biologics that can address unmet medical needs and improve patient outcomes.

Amgen is a US-based biotechnology company that develops and manufactures biologic drugs for the treatment of cancer, autoimmune diseases, and other conditions. Some of its major biologic products include Enbrel, Neulasta, and Epogen.

AbbVie is a US-based pharmaceutical company that specializes in the development and manufacture of biologic drugs for the treatment of autoimmune diseases, cancer, and other conditions. Some of its major biologic products include Humira, Imbruvica, and Venclexta.

Novo Nordisk is a Danish multinational pharmaceutical company that is a major player in the biologics market. The company specializes in the development and manufacture of biologic drugs for the treatment of diabetes, obesity, and other conditions. Some of its major biologic products include Victoza, Ozempic, and NovoSeven.

In December 2020, AstraZeneca announced its acquisition of Alexion Pharmaceuticals for $39 billion. Alexion specializes in the development and manufacture of biologic drugs for the treatment of rare diseases, which will help to expand AstraZeneca's portfolio in this area.

In October 2020, Gilead Sciences announced its acquisition of Immunomedics for $21 billion. Immunomedics specializes in the development and manufacture of biologic drugs for the treatment of cancer, which will help to expand Gilead's portfolio in this area.

In November 2020, Pfizer and BioNTech announced the development of a COVID-19 vaccine, which was authorized for emergency use in the United States and other countries. The vaccine is based on biologic technology, specifically messenger RNA (mRNA) technology.

In January 2021, Sanofi announced its acquisition of Kiadis Pharma, a biotech company that specializes in the development of cell-based immunotherapies for the treatment of cancer. This acquisition will help to expand Sanofi's portfolio in the area of cancer immunotherapy.

Segmentation Analysis of The Global Biologics Market 2022-2030

The report forecasts revenue growth at global, regional, and country matrics and analyzes the latest industry trends in each of the sub-segments ranging from 2016-2030. For this, CDI has segmented the global Biologics market report based on capacity, vehicle, application, and propulsion type along with regional analysis.

Product Outlook (Revenue, USD Billion; 2014 - 2025)

• Monoclonal Antibodies
• Diagnostic
• Biochemical Analysis
• Diagnostic Imaging
• Therapeutic
• Direct MAB Agents
• Targeting MAB Agents
• Protein Purification
• Others

MABs by type

• Murine
• Chimeric
• Humanized
• Human
• Others

Vaccines

• Recombinant Proteins
• Antisense, RNAi, & Molecular Therapy
• Others

Disease Category Outlook (Revenue, USD Billion; 2014 - 2025)

• Vaccines
• MABs
• Antisense, RNAi, & Molecular Therapy
• Recombinant Proteins
• Others

Immunological Disorders

• Cardiovascular Disorders
• Hematological Disorders
• Others

Biologics Manufacturing Outlook (Revenue, USD Billion; 2014 - 2025)

• Outsourced
• In-house

Regional Outlook (Revenue, USD Million, 2017 - 2030)

By Region

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America